Clinical trials: Dry Eye Symptoms
Ocular Pain, Dry Eye
Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
The purpose of this study is to determine whether SYL1001 is safe for the prevention and treatment of ocular pain and dry eye syndrome.
- Trial name
- NCT01438281
- Testing
- SYL1001
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Dry Eye Syndrome
LacriFill Canalicular Occlusion for Dry Eye After LASIK
This study is a single-site, prospective, randomized (2:1) controlled study of subjects aged 18-39 who are candidates for bilateral LASIK and have dry eye symptoms (OSDI ≥13).
- Trial name
- NCT07911930
- Testing
- LacriFill Canalicular Filler
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mann Eye Institute
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Dry Eye Syndromes, Meige Syndrome
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.
- Conditions
- Dry Eye Syndromes, Meige Syndrome, Blepharospasm, Hyperactivity
- Trial name
- NCT05618470
- Testing
- Wumeiwan Jiawei Fang, botulinum toxin A
- Where
- China
- Volunteers
- 80 people
- Sponsor
- China Academy of Chinese Medical Sciences
Dry Eye
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality
To evaluate and compare the effects of PEG-400 based artificial tear and Systane tears in mild-moderate dry eye patients. TBUT, Visual impact and subjective evaluations will be assessed in this month long trial.
- Trial name
- NCT00622037
- Testing
- PEG-400 based artificial tear, Systane
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Bp Consulting, Inc
Dry Eye Disease (DED)
Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon
To evaluate the impact of Acoltremon 0.003% on subjective dry eye symptoms using validated patient-reported outcome measures: Eye Dryness Score Visual Analog Scale (EDS-VAS).
- Trial name
- ASTRA (NCT07268599)
- Testing
- Acoltremon
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Colvard Kandavel Eye Center
Dry Eye
Effect of Povidone-iodine 5% Vs 1% on the Ocular Surface in Intravitreal Injections of Anti-VEGF
Objective and subjective comparison between the use of povidone-iodine 1% vs 5% as antiseptic in patients that need anti-VEGF intravitreal injection
- Trial name
- anti-VEGF (NCT06710951)
- Testing
- Change of normal concentration of povidone-iodine 5% to 1%
- Where
- Mexico
- Volunteers
- 88 people
- Sponsor
- José Gerardo García Aguirre
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Pain, Dry Eye Syndrome
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
The aim of this pilot study is to compare the analgesic effect of two strengths of SYL1001 eye drops versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.
- Trial name
- NCT02455999
- Testing
- SYL1001
- Where
- 6 sites in Estonia, Spain
- Volunteers
- 66 people
- Sponsor
- Sylentis, S.A.
Dry Eye Disease
Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects
The objective of this exploratory study is to determine the safety and efficacy of 0.002% Naltrexone Ophthalmic Solution, compared to placebo for the treatment of the signs and symptoms of dry eye in diabetic subjects.
- Trial name
- NCT03660475
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sassani, Joseph S., MD, MHA
Maculopathy
AVIGA3 (Cohort 2.0)
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central…
- Trial name
- AVIGA3 (NCT07255859)
- Testing
- Amsler Grid, AVIGA
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- Tan Tock Seng Hospital
Long Term Follow up Dry Eye Disease
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).
- Trial name
- NCT03920215
- Testing
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Oyster Point Pharma, Inc.
Dry Eye Syndrome (DES)
Dietary Supplementation on Tear Secretion and Inflammation in DES
The goal of this clinical trial is to explore the effect of supplementation of fish oil, lutein and zeaxanthin on the symptoms of dry eye syndrome, antioxidant capacity, oxidative stress and anti-inflammatory capacity in DES…
- Trial name
- DES (NCT06738446)
- Testing
- Multicomponent dietary supplement group
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Shih Chien Huang
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome, Fatigue
Fatigue in Primary Sjögren's Syndrome
Fatigue is a common clinical finding in Primary Sjögren's syndrome (PSS). In PSS, there is not enough data about the conditions in which fatigue develops and which clinical conditions the disease is associated with.
- Conditions
- Sjogren's Syndrome, Fatigue, Pain Syndrome, Depression
- Trial name
- NCT04802577
- Testing
- FACT-F questionnaire, Beck Depression Inventory, Beck Anxiety Inventory
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Dry Eye Disease (DED)
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
- Trial name
- NCT03333057
- Testing
- NOV03
- Where
- 11 sites in United States
- Volunteers
- 336 people
- Sponsor
- Novaliq GmbH
Dry Eye Syndromes, Eye Diseases
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
- Trial name
- NCT05814757
- Testing
- OTX-DED, Controlled Insertion, Collagen Punctal Plug
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Disease (DED)
Effectiveness of Systane PRO for Mild to Moderate Dry Eye Disease
The primary objective of this study is to show that consistent use of Systane PRO over a 30 period will significantly improve the signs and symptoms of Dry Eye Disease and decrease patients' ocular surface disease index score for…
- Trial name
- SYSTANEPRO1 (NCT07639034)
- Testing
- Systane Pro Topical Ophthalmic
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Gordon Schanzlin New Vision
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals